Oruka Therapeutics Psoriasis Drug Clears Skin in 61% of Patients in Phase 2 Trial

07:58 AM EDT, 10/26/2026 (MT Newswires) -- Oruka Therapeutics (ORKA) said Monday its experimental psoriasis drug ORKA-001 achieved complete skin clearance in 61% of patients receiving the high dose in a phase 2b trial at Week 16, versus 0% for placebo. The 600 mg dose also helped 86% of patients achieve at least 90% skin clearance, the company said. The company said it recorded no serious adverse events in the high-dose group and plans to discuss phase 3 development with regulators, targeting trial launches in H1 2027.